相似文献
1
Genomic markers to tailor treatments: waiting or initiating?
Hum Genet. 2011 Jul;130(1):15-8. doi: 10.1007/s00439-011-0986-9. Epub 2011 Apr 13.
2
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
3
Large-Scale Genomic Biobanks and Cardiovascular Disease.
Curr Cardiol Rep. 2018 Mar 8;20(4):22. doi: 10.1007/s11886-018-0969-8.
4
Population genetic considerations for using biobanks as international resources in the pandemic era and beyond.
BMC Genomics. 2021 May 17;22(1):351. doi: 10.1186/s12864-021-07618-x.
5
What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?
Oncologist. 2010;15 Suppl 1:19-23. doi: 10.1634/theoncologist.2010-S1-19.
6
Harmonising and linking biomedical and clinical data across disparate data archives to enable integrative cross-biobank research.
Eur J Hum Genet. 2016 Apr;24(4):521-8. doi: 10.1038/ejhg.2015.165. Epub 2015 Aug 26.
7
[Current Condition and Issues of Clinical Biobanks in Japan -From the Point of View of Laboratory Medicine-].
Rinsho Byori. 2017 Feb;65(2):181-189.
8
Ethical pitfalls in neonatal comparative effectiveness trials.
Neonatology. 2014;105(4):350-1. doi: 10.1159/000360650. Epub 2014 May 30.
9
The need for large-scale randomized evidence.
Br J Clin Pharmacol. 1997 Apr;43(4):349-53. doi: 10.1046/j.1365-2125.1997.00569.x.
10
The project data sphere initiative: accelerating cancer research by sharing data.
Oncologist. 2015 May;20(5):464-e20. doi: 10.1634/theoncologist.2014-0431. Epub 2015 Apr 15.
引用本文的文献
1
Tubal flushing with oil- or water-based contrast medium: can we identify markers that indicate treatment benefit?
Hum Reprod Open. 2019 Jul 18;2019(3):hoz015. doi: 10.1093/hropen/hoz015. eCollection 2019.
2
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
J Pers Med. 2017 Jan 25;7(1):1. doi: 10.3390/jpm7010001.
3
Designing a study to evaluate the benefit of a biomarker for selecting patient treatment.
Stat Med. 2015 Nov 30;34(27):3503-15. doi: 10.1002/sim.6564. Epub 2015 Jun 25.
4
Current and future management of diabetic retinopathy: a personalized evidence-based approach.
Diabetes Manag (Lond). 2013 Nov 1;3(6):481-494. doi: 10.2217/dmt.13.50.
5
Mechanism of inflammation in age-related macular degeneration: an up-to-date on genetic landmarks.
Mediators Inflamm. 2013;2013:435607. doi: 10.1155/2013/435607. Epub 2013 Nov 27.
6
What's out there making us sick?
J Environ Public Health. 2012;2012:605137. doi: 10.1155/2012/605137. Epub 2011 Oct 24.
本文引用的文献
1
Measuring the performance of markers for guiding treatment decisions.
Ann Intern Med. 2011 Feb 15;154(4):253-9. doi: 10.7326/0003-4819-154-4-201102150-00006.
2
9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response.
Nature. 2011 Feb 10;470(7333):264-8. doi: 10.1038/nature09753.
3
Charting a course for genomic medicine from base pairs to bedside.
Nature. 2011 Feb 10;470(7333):204-13. doi: 10.1038/nature09764.
4
Initial impact of the sequencing of the human genome.
Nature. 2011 Feb 10;470(7333):187-97. doi: 10.1038/nature09792.
5
Genomics and the continuum of cancer care.
N Engl J Med. 2011 Jan 27;364(4):340-50. doi: 10.1056/NEJMra0907178.
6
Bring on the biomarkers.
Nature. 2011 Jan 13;469(7329):156-7. doi: 10.1038/469156a.
7
Where will new drugs come from?
Lancet. 2011 Jan 8;377(9760):97. doi: 10.1016/S0140-6736(11)60001-9.
8
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.
9
Genome-wide association studies and large-scale collaborations in epidemiology.
Eur J Epidemiol. 2010 Aug;25(8):525-9. doi: 10.1007/s10654-010-9487-8. Epub 2010 Jul 11.
10
Maximizing scientific knowledge from randomized clinical trials.
Am Heart J. 2010 Jun;159(6):937-43. doi: 10.1016/j.ahj.2010.03.002.
Zotero 插件